Please ensure Javascript is enabled for purposes of website accessibility

Quest Diagnostics Rolls Out Home COVID-19 Antibody Test for Purchase Online

By Eric Volkman - Updated Apr 29, 2020 at 7:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immune Response test retails for $119.

Medical testing specialist Quest Diagnostics (DGX -1.36%) has rolled out a product that is likely to find a large customer base in a hurry. The company announced Tuesday that its QuestDirect unit is now offering for sale the COVID-19 Immune Response, an antibody test for consumers. This can be purchased online at a dedicated page of QuestDirect's website; it retails for $119.

An antibody is a protein used by the immune system to fight pathogens. One common antibody, immunoglobulin G (IgG), derives from exposure to COVID-19, and it is this antibody that the COVID-19 Immune Response detects.

A coronavirus colony.

Image source: Getty Images.

A potential user has to request a COVID-19 Immune Response test. This involves filling out a brief questionnaire on the dedicated web page that gauges suitability for the test. Quest said that if the request passes a review and is deemed appropriate, a licensed doctor will issue an order for testing.

Once the results are obtained, customers can opt to discuss them with a licensed doctor. The results can be accessed through a different Quest portal; the company said they are typically available one or two days after a blood draw is received (this can be done by appointment at any Quest Diagnostics patient service center).

In the press release announcing the test, which is already available for purchase, Quest wrote that "[w]hile the science on COVID-19 is evolving, testing for antibodies may identify people who have likely been exposed to COVID-19 and might have mounted an immune response to the virus.  Our goal is to empower individuals and their physicians to make informed decisions about their risk of infection and of spreading the virus."

On Tuesday, Quest shares fell 3.5%. This was a steeper drop than that of the broader equities market and numerous peer healthcare stocks

 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
DGX
$135.96 (-1.36%) $-1.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.